J 2017

Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies

KRALICKOVA, P., J. KUHNOVA, O. SOUCEK, P. VODAREK, P. ZAK et. al.

Základní údaje

Originální název

Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies

Autoři

KRALICKOVA, P. (203 Česká republika), J. KUHNOVA (203 Česká republika), O. SOUCEK (203 Česká republika), P. VODAREK (203 Česká republika), P. ZAK (203 Česká republika), M. SIMKOVIC (203 Česká republika), M. MOTYCKOVA (203 Česká republika), L. SMOLEJ (203 Česká republika), E. MALA (203 Česká republika), C. ANDRYS (203 Česká republika), J. KREJSEK (203 Česká republika) a Vojtěch THON (203 Česká republika, garant, domácí)

Vydání

Journal of Immunology Research, London, Hindawi, 2017, 2314-8861

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30102 Immunology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.298

Kód RIV

RIV/00216224:14110/17:00099077

Organizační jednotka

Lékařská fakulta

UT WoS

000419035800001

Klíčová slova anglicky

Pneumococcal Capsular Polysaccharides; Natural Anti-Galactosyl; Humoral Immunodeficiencies

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 21. 3. 2018 16:27, Soňa Böhmová

Anotace

V originále

Humoral deficiencies represent a broad group of disorders. The aim of the study was to compare the levels of antibodies against pneumococcal capsular polysaccharides (anti-PCP) and natural anti-galactosyl (anti-Gal) antibodies in (1) patients with chronic lymphocytic leukaemia (CLL), (2) patients with common variable immunodeficiency (CVID), and (3) a healthy population and to explore their diagnostic and prognostic potential. Serum immunoglobulin levels and levels of anti-Gal IgG, IgA, and IgM and anti-PCP IgG and IgG2 were determined in 59 CLL patients, 30 CVID patients, and 67 healthy controls. Levels of IgG, IgA, IgM, anti-Gal IgA, anti-Gal IgM, and anti-PCP IgA were lower in CLL and CVID patients than in healthy controls. Decrease in the levels of IgA, IgM, anti-Gal IgA, and anti-PCP IgA was less pronounced in the CLL group than in the CVID group. IgA decline, anti-Gal IgA, anti-PCP IgA, and anti-PCP IgG2 were negatively correlated with CLL stage. We devise the evaluation of anti-Gal antibodies to be a routine test in humoral immunodeficiency diagnostics, even in cases of immunoglobulin substitution therapy. Significant reductions, mainly in anti-Gal IgA, IgM, and anti-PCP IgA levels, may have prognostic importance in CLL patients.